Aera Therapeutics
AERA-109 is a targeted-LNP in vivo CAR-T candidate for B-cell-mediated autoimmune diseases, supported by mouse and nonhuman-primate studies. The pipeline projects clinical entry in the second half of 2026; a projected date is not proof that dosing has begun.
Corporate information
- Company entity
- Aera Therapeutics
- Headquarters / principal office
- Cambridge, MASelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- Not verified
- Ownership / capital status
- PrivatePrivately financed; combined Series A and B disclosed ↗
- Official corporate reference
- https://aeratx.com/pipeline/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2023-02-16 · Combined Series A and B · US$193 million combined ↗
Combined financing announced at public launch, not a single Series B amount. The public-launch date is not assigned as the legal founding date; later undisclosed rounds are not excluded.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
AERA-109 is a targeted-LNP in vivo CAR-T candidate for B-cell-mediated autoimmune diseases, supported by mouse and nonhuman-primate studies. The pipeline projects clinical entry in the second half of 2026; a projected date is not proof that dosing has begun.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Aera Therapeutics — primary program / ownership disclosure
- Aera Therapeutics — official company page
- Aera $193 million combined Series A and B — February 16, 2023
- Company-managed LinkedIn profile — self-reported location